Gossamer Bio (NASDAQ:GOSS) Earns Buy Rating from Chardan Capital

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reiterated by Chardan Capital in a research note issued to investors on Monday, Benzinga reports.

Other analysts have also issued research reports about the company. Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Weiss Ratings raised Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research note on Tuesday, July 28th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $240.00.

Gossamer Bio Price Performance

Shares of NASDAQ:GOSS opened at $9.60 on Monday. The company’s fifty day moving average price is $11.48 and its 200-day moving average price is $16.16. The firm has a market capitalization of $58.67 million, a price-to-earnings ratio of -0.17 and a beta of 2.21. Gossamer Bio has a one year low of $8.29 and a one year high of $309.60.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds have recently modified their holdings of GOSS. Corient Private Wealth LP boosted its holdings in Gossamer Bio by 41.3% in the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock valued at $927,000 after acquiring an additional 1,647,315 shares in the last quarter. Bank of America Corp DE bought a new stake in Gossamer Bio in the second quarter valued at $65,000. Hsbc Holdings PLC boosted its holdings in Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock valued at $267,000 after acquiring an additional 1,469,175 shares in the last quarter. Kalehua Capital Management LLC bought a new stake in Gossamer Bio in the first quarter valued at $3,363,000. Finally, BlackRock Inc. bought a new stake in Gossamer Bio in the second quarter valued at $1,262,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.